Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VNN1 | O95497 | 1/20 | 0.62 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.55 |
| ▸ | NAMPT | P43490 | 2/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | HPGDS | O60760 | 2/20 | 0.53 |
| ▸ | ITK | Q08881 | 3/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL166484 | 0.82 | LMNA (0.82) | NPC1LMNAPOLBRAB9AMAPK14 | |
| SCHEMBL16598445 | 0.82 | HTT (0.66) | POLBCYP2C9MEN1KMT2AALDH1A1 | |
| Hydrochloric Acid SCHEMBL27843329 | 0.81 | LMNA (0.80) | NPC1LMNAPOLBRAB9AMAPK14 | |
| SCHEMBL1933893 | 0.80 | HDAC3 (0.51) | VNN1NAMPTCYP2C9HPGDSHDAC3 | |
| SCHEMBL13164056 | 0.80 | KMT2A (0.63) | VNN1LMNARAB9ANAMPTCYP2C9 | |
| SCHEMBL29415439 | 0.79 | NPC1 (0.63) | NPC1LMNAPOLBRAB9AMAPK14 | |
| SCHEMBL998521 | 0.79 | NPC1 (0.63) | NPC1LMNAPOLBRAB9AMAPK14 | |
| SCHEMBL16597986 | 0.79 | SMN1; SMN2 (0.67) | LMNAPOLBRAB9ACYP2C9HDAC3 | |
| SCHEMBL12484783 | 0.78 | NAMPT (0.61) | NPC1LMNAPOLBRAB9AMAPK14 | |
| SCHEMBL5791965 | 0.77 | P2RX3 (0.53) | NPC1LMNAPOLBRAB9AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107207493-A | Substituted pyrrolopyridines as bromodomain inhibitors | 基因泰克公司 | 2017-09-26 | — | — | CN | claimed |
| US-11844779-B2 | PKC-Delta-I inhibitor formulations and uses thereof | UNIVERSITY OF SOUTH FLORIDA (US) | 2023-12-19 | — | — | US | disclosed |
| US-11261185-B2 | Bicyclic heterocyclic derivatives | MERCK PATENT GMBH (DE) | 2022-03-01 | — | — | US | disclosed |
| US-20210401802-A1 | PKC-DELTA-I INHIBITOR FORMULATIONS AND USES THEREOF | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS OFFICE OF GENERAL COUNSEL - PSG IV (024) | 2021-12-30 | — | — | US | disclosed |
| US-11129808-B2 | PKC-delta-I inhibitor formulations and uses thereof | UNIVERSITY OF SOUTH FLORIDA (US) | 2021-09-28 | — | — | US | disclosed |
| US-20210002278-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES | MERCK PATENT GMBH (DE) | 2021-01-07 | — | — | US | disclosed |
| US-20210002278-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES | MERCK PATENT GMBH (DE) | 2021-01-07 | — | — | US | disclosed |
| US-10829489-B2 | Bicyclic heterocyclic derivatives | MERCK PATENT GMBH (DE) | 2020-11-10 | — | — | US | disclosed |
| US-10829489-B2 | Bicyclic heterocyclic derivatives | MERCK PATENT GMBH (DE) | 2020-11-10 | — | — | US | disclosed |
| US-20200062756-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES | MERCK PATENT GMBH (DE) | 2020-02-27 | — | — | US | disclosed |
| WO-2017020981-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES | MERCK PATENT GMBH (DE) | 2017-02-09 | — | — | WO | disclosed |
| WO-2017020981-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES | MERCK PATENT GMBH (DE) | 2017-02-09 | — | — | WO | disclosed |
| EP-2303876-B1 | DIKETO AZOLOPIPERIDINES AND AZOLOPIPERAZINES AS ANTI-HIV AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2014-03-19 | — | — | EP | disclosed |
| US-8124615-B2 | Diketo substituted pyrrolo[2,3-C]pyridines | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-02-28 | — | — | US | disclosed |
| US-20110212971-A1 | DIKETO FUSED AZOLOPIPERIDINES AND AZOLOPIPERAZINES AS ANTI-HIV AGENTS | BRISTOL-MYERS SQUIBB COMPANY | 2011-09-01 | — | — | US | disclosed |
| US-7960406-B2 | Diketo substituted pyrrolo[2,3-c] pyridines | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-06-14 | — | — | US | disclosed |
| US-7960406-B2 | Diketo substituted pyrrolo[2,3-c] pyridines | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-06-14 | — | — | US | disclosed |
| US-20100009993-A1 | Diketo Fused Azolopiperidines and Azolopiperazines as Anti-HIV Agents | BRISTOL-MYERS SQUIBB COMPANY | 2010-01-14 | — | — | US | disclosed |
| US-20100009993-A1 | Diketo Fused Azolopiperidines and Azolopiperazines as Anti-HIV Agents | BRISTOL-MYERS SQUIBB COMPANY | 2010-01-14 | — | — | US | disclosed |
| WO-2009158394-A1 | DIKETO AZOLOPIPERIDINES AND AZOLOPIPERAZINES AS ANTI-HIV AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210002278-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES | PDK1, PDK2, PDK3 | VNN1 3693/4885NPC1 1821/4885LMNA 1106/4885 |
| US-20200062756-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES | PDK1, PDK2, PDK3 | VNN1 3693/4885NPC1 1821/4885LMNA 1106/4885 |
| US-20110212971-A1 | DIKETO FUSED AZOLOPIPERIDINES AND AZOLOPIPERAZINES AS ANTI-HIV AGENTS | DHFR, DHPS, DCK | VNN1 3273/4885NPC1 3047/4885LMNA 4593/4885 |
| US-11844779-B2 | PKC-Delta-I inhibitor formulations and uses thereof | PRKCA, PRKCQ, PRKCZ | VNN1 3419/4885NPC1 1765/4885LMNA 873/4885 |
| US-20210401802-A1 | PKC-DELTA-I INHIBITOR FORMULATIONS AND USES THEREOF | PRKCA, PRKCQ, PRKCZ | VNN1 3419/4885NPC1 1765/4885LMNA 873/4885 |
| US-11129808-B2 | PKC-delta-I inhibitor formulations and uses thereof | PRKCA, PRKCQ, PRKCZ | VNN1 3419/4885NPC1 1765/4885LMNA 873/4885 |
| US-10829489-B2 | Bicyclic heterocyclic derivatives | PDK1, PDK2, PDK3 | VNN1 3693/4885NPC1 1821/4885LMNA 1106/4885 |
| US-20100009993-A1 | Diketo Fused Azolopiperidines and Azolopiperazines as Anti-HIV Agents | DHFR, DHPS, DCK | VNN1 3273/4885NPC1 3047/4885LMNA 4593/4885 |
| US-11261185-B2 | Bicyclic heterocyclic derivatives | PDK1, PDK2, PDK3 | VNN1 3693/4885NPC1 1821/4885LMNA 1106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.